In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

Li, Jiehan; Luo, Guang; Zhang, Chuchu; Long, Shuaiyu; Guo, Linghong; Yang, Ge; Wang, Feng; Zhang, Lingling; Shi, Liyang; Fu, Yang; Zhang, Yingjie

doi:10.1016/j.mtbio.2022.100238

Cited by 16 publications

(7 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The notable research outlined in the literature demonstrates that Kang et al developed an injectable, thermally responsive hydrogel nanocomposite for the treatment of glioblastoma multiforme Figure 2(a) [32]. Following surgical intervention, the injection of this hydrogel nanocomposite into the excised tumor site enables it to transition rapidly from a liquid to a gel state at body temperature [33]. This nanocomposite is not only responsive to thermal changes but also functions as a soft, deep intracortical reservoir for drug delivery, thereby facilitating the elimination of tumor cells post-operatively [34][35][36].…”

Section: Injectable Hydrogelsmentioning

confidence: 99%

Advances in Hydrogels of Drug Delivery Systems for Local Treatment of Brain Tumors

Yang,

Wang,

et al. 2024

Preprint

View full text Add to dashboard Cite

The management of brain tumors presents numerous challenges, despite the employment of multimodal therapies including surgical intervention, radiotherapy, chemotherapy, and immunotherapy. Owing to the distinct location of brain tumors and the presence of the blood-brain barrier (BBB), these tumors exhibit considerable heterogeneity and invasiveness at a histological level. Recent advancements in hydrogel research for the local treatment of brain tumors have sought to overcome the primary challenge of delivering therapeutics past the BBB, thereby ensuring efficient accumulation within brain tumor tissues. This article elaborates on various hydrogel-based delivery vectors, examining their efficacy in the local treatment of brain tumors. Additionally, it reviews the fundamental principles involved in designing intelligent hydrogels that can circumvent the BBB and penetrate larger tumor areas, thereby facilitating precise, controlled drug release. Hydrogel-based drug delivery systems (DDSs) are posited to offer a groundbreaking approach in addressing the challenges and limitations inherent in traditional oncological therapies, which are significantly impeded by the unique structural and pathological characteristics of brain tumors.

show abstract

Section: Injectable Hydrogelsmentioning

confidence: 99%

Advances in Hydrogels of Drug Delivery Systems for Local Treatment of Brain Tumors

Yang,

Wang,

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…After using DAB chromogenic agent, dehydrate the tissue, and use neutral gum chip. The results were obtained under the optical microscope by three experienced researchers [51].…”

Section: Immunohistochemistry Stainingmentioning

confidence: 99%

Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer

Zhang,

Mi,

Wang

et al. 2023

Cell Death Discov.

Self Cite

View full text Add to dashboard Cite

Ferroptosis is a new type of iron-dependent programmed cell death induced by lipid peroxidation. However, the underlying mechanisms and function in tumor therapy still remain undisclosed especially in post-transcription regulation. Here, we found that targeting AKT significantly induced GPX4 dependent ferroptosis and suppressed colorectal cancer growth both in vitro and in vivo. During this process, demethylase FTO was downregulated, which increased the m6A methylation level of GPX4, subsequently recognized by YTHDF2 and degraded. Prediction results showed that there are three potential methylated sites (193/647/766), and 193 site was identified as the right one, which was demethylated by FTO and read by YTHDF2. In parallel, AKT inhibition caused the accumulation of ROS which had a negative feedback on GPX4 expression. In addition, protective autophagy was initiated by MK2206 stimulation, while blocking autophagy further increased ferroptosis and markedly enhanced the anti-tumor activity of MK2206. In a word, inhibiting AKT activated ferroptosis through FTO/YTHDF2/GPX4 axis to suppress colon cancer progression, which raised FTO/GPX4 as potential biomarkers and targets in colorectal cancer therapy.

show abstract

“…In addition, less dangerous reactions were also noticeable in patients, such as fever, fatigue, back pain, headache, shivering, and lymphopenia [ 114 ]. Therefore, the topical or intratumoral usage of these drugs is considered, especially in combination with other substances such as immune checkpoint inhibitors or cytostatics [ 115 , 116 ]. Despite the local use of these drugs, systemic effects have been noticed, but they seem to be useful in this case.…”

Section: Tlr Agonists In Oncologymentioning

confidence: 99%

“…In order to prevent side effects after the systemic administration of TLR agonists, new methods of administering them are currently being researched to reduce the exposure of the patient’s healthy tissues to drugs and to better confine the drugs to the tumor. For this purpose, the use of liposomes [ 132 , 133 , 134 ], hydrogels [ 116 , 135 ], immune implants [ 136 ], and pH-responsive nanoparticles [ 137 ], which include a TLR agonist alone or in combination with other drugs, is being investigated.…”

Section: Tlr Agonists As Future Targets In Cancer Therapymentioning

confidence: 99%

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies

et al. 2023

View full text Add to dashboard Cite

Toll-like receptors (TLR) belong to the pattern recognition receptors (PRR). TLR7 and the closely correlated TLR8 affiliate with toll-like receptors family, are located in endosomes. They recognize single-stranded ribonucleic acid (RNA) molecules and synthetic deoxyribonucleic acid (DNA)/RNA analogs—oligoribonucleotides. TLRs are primarily expressed in hematopoietic cells. There is compiling evidence implying that TLRs also direct the formation of blood cellular components and make a contribution to the pathogenesis of certain hematopoietic malignancies. The latest research shows a positive effect of therapy with TRL agonists on the course of hemato-oncological diseases. Ligands impact activation of antigen-presenting cells which results in production of cytokines, transfer of mentioned cells to the lymphoid tissue and co-stimulatory surface molecules expression required for T-cell activation. Toll-like receptor agonists have already been used in oncology especially in the treatment of dermatological neoplastic lesions. The usage of these substances in the treatment of solid tumors is being investigated. The present review discusses the direct and indirect influence that TLR7/8 agonists, such as imiquimod, imidazoquinolines and resiquimod have on neoplastic cells and their promising role as adjuvants in anticancer vaccines.

show abstract

In situ injectable hydrogel-loaded drugs induce anti-tumor immune responses in melanoma immunochemotherapy

Cited by 16 publications

References 94 publications

Advances in Hydrogels of Drug Delivery Systems for Local Treatment of Brain Tumors

Advances in Hydrogels of Drug Delivery Systems for Local Treatment of Brain Tumors

Targeting AKT induced Ferroptosis through FTO/YTHDF2-dependent GPX4 m6A methylation up-regulating and degradating in colorectal cancer

The Role of TRL7/8 Agonists in Cancer Therapy, with Special Emphasis on Hematologic Malignancies

Contact Info

Product

Resources

About